HER2-targeted therapies, including trastuzumab (Herceptin) and lapatinib (Tykerb) are commonly used in the clinic and have dramatically improved the survival of BC patients with HER2-overexpressing (HER2-positive) tumors [3, 4]. Here, ERBB2 is linked to breast cancer.